BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19627190)

  • 1. Innate immune control of nucleic acid-based vaccine immunogenicity.
    Koyama S; Coban C; Aoshi T; Horii T; Akira S; Ishii KJ
    Expert Rev Vaccines; 2009 Aug; 8(8):1099-107. PubMed ID: 19627190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.
    Ishii KJ; Kawagoe T; Koyama S; Matsui K; Kumar H; Kawai T; Uematsu S; Takeuchi O; Takeshita F; Coban C; Akira S
    Nature; 2008 Feb; 451(7179):725-9. PubMed ID: 18256672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
    Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.
    Lahiri A; Das P; Chakravortty D
    Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants.
    Olive C
    Expert Rev Vaccines; 2012 Feb; 11(2):237-56. PubMed ID: 22309671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The science of adjuvants.
    Kwissa M; Kasturi SP; Pulendran B
    Expert Rev Vaccines; 2007 Oct; 6(5):673-84. PubMed ID: 17931149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity of viral haemorragic septicaemia rhabdovirus (VHSV) DNA vaccines can depend on plasmid regulatory sequences.
    Chico V; Ortega-Villaizan M; Falco A; Tafalla C; Perez L; Coll JM; Estepa A
    Vaccine; 2009 Mar; 27(13):1938-48. PubMed ID: 19368775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostimulatory DNA as a vaccine adjuvant.
    Higgins D; Marshall JD; Traquina P; Van Nest G; Livingston BD
    Expert Rev Vaccines; 2007 Oct; 6(5):747-59. PubMed ID: 17931155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis.
    Bergmann-Leitner ES; Leitner WW; Duncan EH; Savranskaya T; Angov E
    Vaccine; 2009 Sep; 27(41):5700-8. PubMed ID: 19576940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-like particle vaccines and adjuvants: the HPV paradigm.
    Buonaguro FM; Tornesello ML; Buonaguro L
    Expert Rev Vaccines; 2009 Oct; 8(10):1379-98. PubMed ID: 19803760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII.
    Ramanathan MP; Kutzler MA; Kuo YC; Yan J; Liu H; Shah V; Bawa A; Selling B; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Jul; 27(32):4370-80. PubMed ID: 19497647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met as a novel adjuvant for DNA vaccine.
    Lee CG; Choi SY; Park SH; Park KS; Ryu SH; Sung YC
    Vaccine; 2005 Sep; 23(38):4703-10. PubMed ID: 15936851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular detection and immune signaling pathways of DNA vaccines.
    Tang CK; Pietersz GA
    Expert Rev Vaccines; 2009 Sep; 8(9):1161-70. PubMed ID: 19722890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine adjuvants revisited.
    Aguilar JC; Rodríguez EG
    Vaccine; 2007 May; 25(19):3752-62. PubMed ID: 17336431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll or toll-free adjuvant path toward the optimal vaccine development.
    Ishii KJ; Akira S
    J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvants for porcine reproductive and respiratory syndrome virus vaccines.
    Charerntantanakul W
    Vet Immunol Immunopathol; 2009 May; 129(1-2):1-13. PubMed ID: 19157569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccines expressing antigens with a stress protein-capturing domain display enhanced immunogenicity.
    Reimann J; Schirmbeck R
    Immunol Rev; 2004 Jun; 199():54-67. PubMed ID: 15233726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines.
    Wang C; Ge Q; Ting D; Nguyen D; Shen HR; Chen J; Eisen HN; Heller J; Langer R; Putnam D
    Nat Mater; 2004 Mar; 3(3):190-6. PubMed ID: 14991022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle.
    Kovacs-Nolan J; Mapletoft JW; Latimer L; Babiuk LA; Hurk Sv
    Vaccine; 2009 Mar; 27(14):2048-54. PubMed ID: 19428829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic applications of nucleic acids as ligands for Toll-like receptors.
    Panter G; Kuznik A; Jerala R
    Curr Opin Mol Ther; 2009 Apr; 11(2):133-45. PubMed ID: 19330719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.